Inflexion completed the acquisition of Rosemont Pharmaceuticals from Perrigo for $195m.

Inflexion completed the acquisition of Rosemont Pharmaceuticals, a liquid pharmaceuticals business, from Perrigo, an Irish–registered manufacturer of private label over-the-counter pharmaceuticals, for $195m. "We are delighted to be partnering with Rosemont on their journey to become a standalone business. Our experience in helping businesses to become independent combined with our success in growing healthcare businesses make us confident our partnership will be an excellent foundation for further innovation and new product development," Simon Turner, Inflexion Managing Partner.